QuVa Pharma, a national supplier of sterile compounding services, has received FDA registration as a 503B facility for its Bloomsbury, NJ facility. The Bloomsbury facility was purchased in October 2016 and has been undergoing renovations to be QuVa’s third manufacturing facility. This marks completion of an initial phase of the development and commercializing of the 160,000 square foot buildings on the site. Subsequent development stages will be completed over 12 months to create one of...